

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usptb.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/071,052	06/04/1993	JEFFRY W. KREAMER	4673120/4650	9541
26386	7590 06/15/2005		EXAM	INER
•	ROWN, KOEHN, SHORS	KIM, JENNIFER M		
THE FINANCIAL CENTER 666 WALNUT STREET			ART UNIT	PAPER NUMBER
SUITE 2500			1617	
DES MOINES, IA 50309-3993			DATE MAILED: 06/15/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

-,	Application No.	Applicant(s)			
	08/071,052	KREAMER, JEFFRY W.			
Office Action Summary	Examiner	Art Unit			
	Jennifer Kim	1617			
The MAILING DATE of this communication ap					
Period for Reply		0,550.4			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 10 F	ebruary 2005.				
2a) ☐ This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.				
,	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) ☐ Claim(s) 30-32 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 30-32 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examine	er.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicationity documents have been received in (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate			
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date)	atent Application (PTO-152)			

DETAILED ACTION

The amendment filed on February 10, 2005 have been received and entered into the application.

Applicant's arguments with respect to claims 30-32 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 30-32 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 30 recites the limitation "multivitamin" in line 8. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and Application/Control Number: 08/071,052

Art Unit: 1617

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 30-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Steiner (Thrombosis and Haemostasis, 1983).

Steiner teaches the effect of vitamin E administration on platelet function in a group comprising administration of combination of vitamin E and aspirin. (Summary). Steiner teaches aspirin was administered 300mg every other day along with increasing vitamin E dosage (400 I.U.-1,200 I.U). It is noted that these dosages are within Applicant's effective dosages set forth in claims 30-32). Steiner teaches that platelet adhesion to collagen was strongly inhibited by a combination of vitamin E and aspirin and this result suggest that the vitamin E administration have a beneficial effect in patients suffering from arterial thromboembolic disease. (summary, page 73, right-hand column first paragraph).

Steiner does not teach the medicament comprising aspirin and vitamin E.

It would have been obvious to one of ordinary skill in the art to formulate the medicament comprising vitamin E and aspirin. One would have been motivated to formulate the medicament comprising aspirin and vitamin E in order to achieve

Art Unit: 1617

beneficial effect in patients suffering form arterial thromboembolic disease because the combination of aspirin and vitamin E therapy strongly inhibited the platelet adhesion to collagen as taught by Steiner. One would have been further motivated to combine aspiring and vitamin E in a single medicament in order to conveniently treat patients suffering from arterial thromboembolic diseases by a single medicament.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 08/071,052

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sreenivasan Padmanabhan Supervisory Examiner Art Unit 1617

Jmk May 20, 2005

SHENGJUN WANG PRIMARY EXAMINER